-
29 October, 2026
Teplizumab, a new treatment to delay the onset of type 1 diabetes, now available at barnaclínic+
barnaclínic+ now offers Teplizumab (Teizeild®), a new treatment for type 1 diabetes that can delay the onset of clinical diabetes in certain patients who have not yet developed symptoms. This new biological therapy represents a paradigm shift in the management of type 1 diabetes, as it makes it possible to target the autoimmune process responsible for destroying insulin-producing cells before treatment for clinical diabetes becomes necessary.
The introduction of Teplizumab expands the options for early treatment of type 1 diabetes at barnaclínic+ and highlights the importance of type 1 diabetes screening and early diagnosis. Identifying people in the early stages of the disease, before symptoms appear, makes it possible to assess new therapeutic options to delay its progression.
Teplizumab makes it possible to target the autoimmune process underlying type 1 diabetes and delay its progression to the clinical stage in eligible patients
